Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 15/20 | 1.00 |
| ▸ | CTSD | P07339 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308465 | 1.00 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL4321237 | 0.90 | BACE1 (0.82) | BACE1BACE2CTSD | |
| SCHEMBL4308469 | 0.89 | BACE1 (0.80) | BACE1BACE2CTSD | |
| SCHEMBL4318807 | 0.88 | BACE1 (0.79) | BACE1BACE2CTSD | |
| SCHEMBL4310763 | 0.88 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL4315255 | 0.87 | BACE1 (0.77) | BACE1BACE2CTSD | |
| SCHEMBL4311762 | 0.87 | BACE1 (0.76) | BACE1BACE2CTSD | |
| SCHEMBL4318717 | 0.87 | BACE1 (0.76) | BACE1BACE2CTSD | |
| SCHEMBL3574659 | 0.86 | BACE1 (0.75) | BACE1BACE2CTSD | |
| SCHEMBL3579018 | 0.85 | BACE1 (0.74) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | BACE1 5/4885BACE2 12/4885CTSD 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.